JOJulián Olalla

Julián Olalla

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julián Olalla has a total of 525 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Digital and AI-Based mHealth Interventions, Including Chatbots, for HIV and STI Prevention Among Men Who Have Sex With Men and LGBTIQ+ Populations: A Critical Narrative Review With Systematic Search (Preprint)

    by Inés Pérez Camacho, María Padilla, Francisco Rivas-Ruíz, Encarnación Hidalgo, Alicia Pardo, María José Martin-Bautista, Almudena Ramírez, Julián Olalla

    BACKGROUND Men who have sex with men (MSM) and LGBTIQ+ populations bear a disproportionate burden of HIV and other sexually transmitted infections (STIs) due to structural stigma and barriers to culturally competent care. Mobile and other digital health technologies, and more recently artificial intelligence (AI)–based tools such as chatbots and risk prediction models, may help improve prevention, testing, and pre-exposure prophylaxis (PrEP) use in these groups. OBJECTIVE This review aimed to (1) synthesize evidence from the past decade on the effectiveness and acceptability of mHealth and other digital sexual health interventions targeting MSM and LGBTIQ+ individuals—focusing on HIV, other STIs, and PrEP—and (2) identify the distinctive features and current evidence base of interventions incorporating AI or advanced automation, particularly conversational agents. METHODS We conducted a critical narrative review with a systematic search following PRISMA recommendations to identify mHealth and other digital sexual health interventions targeting MSM and LGBTIQ+ individuals. Databases searched included PubMed/MEDLINE, Embase, PsycINFO, CINAHL, Web of Science, and the Cochrane Library for studies published between January 1, 2016, and December 31, 2025, complemented by exploratory searches in technology repositories. Eligible studies included MSM and/or LGBTIQ+ participants; evaluated digital sexual health, HIV/STI, or PrEP interventions; and reported quantitative outcomes on behavior, service use, or cognitive/psychosocial variables. Randomized and nonrandomized trials, quasi-experimental, pre–post, pilot, and feasibility studies were included. Two reviewers independently screened records and extracted data. Owing to substantial heterogeneity in designs and outcomes, a narrative synthesis was conducted instead of a meta-analysis. The review protocol was not registered in any public registry. RESULTS Of 12,995 records identified, 15 intervention studies met the inclusion criteria, complemented by 9 recent systematic or scoping reviews on digital and AI-based sexual health interventions. Conventional digital interventions using websites, mobile apps, SMS, social media, and interactive online programs showed modest but relatively consistent improvements in sexual health knowledge, attitudes, HIV/STI testing frequency, and some risk-reduction behaviors among MSM and LGBTIQ+ populations, whereas evidence for PrEP initiation and adherence was sparse and mixed. Interventions explicitly incorporating AI—mainly chatbots for HIV testing support, PrEP decision-making, and sexual health counseling, as well as risk prediction tools often embedded in mobile or web-based platforms—were generally evaluated in pilot or feasibility studies with small samples and short follow-up. These AI-based tools demonstrated high acceptability, perceived confidentiality, and usability, and in some cases facilitated correct HIV self-testing and linkage to services, but robust evidence on sustained behavior change, PrEP uptake and adherence, or clinical outcomes remains very limited. Reporting of equity, data protection, and algorithmic transparency was scarce, and few interventions were specifically co-designed with MSM and LGBTIQ+ communities. CONCLUSIONS Digital and especially mHealth interventions are an established and promising component of HIV and STI prevention for MSM and LGBTIQ+ populations, especially for improving access to information and HIV/STI testing. Evidence on the added value of AI-based tools and conversational agents is still preliminary, largely limited to feasibility and acceptability outcomes, and rarely focused on PrEP. Future research should prioritize rigorously designed, co-designed AI-enhanced mHealth interventions that integrate behavior change theory, ethical safeguards, and equity analyses, and that systematically assess their impact on PrEP initiation and adherence, sexual behaviors, and HIV/STI incidence within community sexual health and HIV prevention services

  • Open Access

    Beyond Surveillance Mutations: Long-Term Trends and Clinical Relevance of Transmitted HIV Drug Resistance in Spain (2007–2023)

    by Paloma Muñoz Báez, Marta Illescas López, Adolfo de Salazar, Iker Falces Romero, Adriana Pinto, Irene Portilla, Mar Masiá, Joaquim Peraire, María Remedios Alemán Valls, Marta Sanchiz, et al.

    Background: While surveillance drug resistance mutations (SDRMs) remain essential for monitoring transmitted drug resistance (TDR), the clinical impact of transmitted resistance for current first-line regimens has become increasingly important. We aimed to update estimates of TDR in Spain and assess its clinical impact over time. Methods: This is a nationwide observational study within the CoRIS cohort. We estimated the prevalence of SDRMs and clinically meaningful resistance (CMR) among antiretroviral therapy (ART)–naïve individuals with baseline genotypic resistance testing in 2022–2023 and evaluated annual trends in CMR to first-line regimens from 2007 to 2023. Clinically meaningful resistance was defined as Stanford HIVDB resistance level ≥ 3. Results: In 2022–2023, 1028 individuals were included; 82.8% were male, 63.2% MSM, and 72.2% subtype B. Surveillance drug resistance mutation prevalence was 14.4% (95% CI 12.2%–16.9%), driven mainly by NNRTI-SDRMs, while INSTI-SDRMs remained rare [0.5% (95% CI 0.1%–1.5%)]; CMR to recommended first-line regimens was very low. Over 2007–2023, CMR declined markedly, coinciding with adoption of second-generation integrase inhibitors. Rilpivirine-associated resistance mutations were detected in 7.0%, largely due to E138A (4.8%). M184V was detected in 0.8%; 6 of 8 cases occurred in persons with current or prior oral pre-exposure prophylaxis (PrEP), although numbers were small. Conclusions: In Spain, TDR remains stable, but its clinical impact on first-line regimens has markedly declined. These findings support Test & Treat strategies and immediate ART initiation with contemporary triple- or dual-drug regimens, while highlighting the need for targeted resistance assessment for rilpivirine-containing regimens and further research on prior PrEP exposure and selected NRTI resistance patterns.

  • Open Access

    Lung Ultrasound Abnormalities and LUS Score After COVID-19 Pneumonia: Determinants and Associations with Dyspnoea in a Prospective Cohort

    by Francisco Navarro-Romero, Cristina Asencio-Méndez, Francisco Rivas-Ruiz, Blanca Sánchez-Mesa, María Dolores Martín-Escalante, Julián Olalla-Sierra

    Background/Objectives: The clinical determinants and functional relevance of persistent lung ultrasound (LUS) abnormalities after COVID-19 pneumonia remain poorly characterized. We aimed to identify determinants of qualitative LUS abnormalities and global lung involvement assessed by the LUS score, and to evaluate their association with persistent dyspnoea. Methods: We conducted a prospective observational study that included 261 patients who were hospitalized for COVID-19 pneumonia and were assessed 1–6 months after discharge. A standardized 14-zone LUS protocol was used to assess qualitative abnormalities (pleural line irregularity, ≥3 B-lines, and subpleural consolidations) and to calculate the LUS score. Associations with clinical variables, including dyspnoea assessed by the modified Medical Research Council (mMRC) scale, were analyzed using multivariable logistic regression. Results: The severity of the acute pneumonia episode emerged as the strongest determinant of qualitative LUS abnormalities and elevated LUS score (>6). Increasing age was independently associated with ultrasound findings. Persistent dyspnoea (mMRC ≥ 1) was associated with all qualitative abnormalities and with a higher prevalence of elevated LUS score (56.6% vs. 22.1%; p < 0.001). A graded association was observed between dyspnoea severity and both qualitative findings and LUS score. An increase in dyspnoea from baseline (ΔmMRC ≥ 1) remained independently associated with an elevated LUS score. Conclusions: Persistent LUS abnormalities are strongly associated with the severity of the acute episode. The LUS score provides a robust, clinically meaningful measure of residual lung involvement and shows a stronger association with persistent dyspnoea than qualitative findings, supporting its role in follow-up and risk stratification.

  • Open Access

    QR code–enabled self-access lifestyle education in older people living with HIV: a pragmatic pilot implementation study. (Preprint)

    by Yamal Jamal-Ismail, Santiago Vico, Javier Pérez-Stachowski, Jimena Abilés, Pedro Alarcón, Javier Arenas-Villafranca, Francisco Rivas-Ruiz, Alfonso Del Arco, María Dolores Martín-Escalante, Julián Olalla


  • Open Access

    Six-month outcomes of a QR Code–Enabled, self-access lifestyle education program to address frailty in older Adults Living With HIV: A prospective single-arm study: A quasi-experimental pre-post study. (Preprint)

    by Yamal Jamal-Ismail, Santiago Vico, Javier Pérez-Stachowski, Jimena Abilés, Pedro Alarcón, Javier Arenas-Villafranca, Francisco Rivas-Ruiz, Alfonso Del Arco, María Dolores Martín-Escalante, Julián Olalla

    BACKGROUND Frailty is prevalent and dynamic among older people living with HIV (PLWH), and it is associated with adverse outcomes. Lifestyle interventions (diet and physical activity) are recommended, but implementation is limited by resources and patient-level barriers. Digital, self-access education may help scale lifestyle support, yet its effectiveness and limitations in older, multimorbid populations remain uncertain. OBJECTIVE To evaluate 6-month changes in frailty phenotype status and related clinical, behavioral, and psychosocial outcomes after a QR code–enabled, self-access lifestyle education program (Mediterranean diet and exercise routines) delivered to PLWH aged ≥60 years. METHODS We conducted a prospective, quasi-experimental, uncontrolled before-and-after study (single-group pre–post design) with a 6-month follow-up in the HIV outpatient clinic of Universitary Hospital Costa del Sol (Marbella, Spain). Participants received a tri-fold leaflet containing QR codes linking to curated YouTube videos with guidance on Mediterranean diet and aerobic/resistance exercise (basic and advanced levels), as an adjunct to usual clinical care. Frailty was assessed using Fried’s Frailty Phenotype (robust, prefrail, frail). Secondary outcomes included changes in individual frailty criteria and patient-reported measures (insomnia severity [ISI], resilience [CD-RISC-10], loneliness [UCLA], anxiety/depression [HADS]), physical activity (IPAQ), Mediterranean diet adherence (The Andalusian Regional Government Mediterranean Diet Adherence Questionnaire), and inflammatory/immunologic markers (eg, IL-6, hsCRP, D-dimer, CD4/CD8 ratio). We described transitions between frailty states and compared baseline vs 6-month values using paired tests: McNemar’s test was used for categorical variables and the paired Student’s t test was used for continuous variables (Wilcoxon signed-rank test in case of non-normal distribution). RESULTS Of 52 enrolled participants at baseline, 50 were included in the 6-month analysis (available-case). Frailty status showed frequent transitions between adjacent states with no direct robust↔frail transitions. Half of frail participants improved to prefrail (2/4), while 20% of prefrail participants improved to robust (5/25). Conversely, 47.6% of robust participants transitioned to prefrail (10/21), and 24% of prefrail participants transitioned to frail (6/25). No statistically significant changes were observed in inflammatory/immunologic markers or physical activity/diet adherence. Insomnia severity improved (ISI median 6.5 to 4; P=.001) and resilience increased (CD-RISC-10 median 32 to 37; P<.001), while loneliness worsened (UCLA median 34.5 to 38; P=.001). Grip strength did not improve among those impaired at baseline. CONCLUSIONS In older PLWH, a QR code–enabled, self-access lifestyle education program was associated with meaningful improvements in insomnia and resilience but did not produce detectable short-term changes in inflammation, physical activity, diet adherence, or grip strength, and loneliness worsened. Frailty remained highly dynamic with bidirectional transitions, supporting the need for multi-component programs that combine scalable digital education with strategies to enhance engagement, resistance training uptake, and social connectedness. CLINICALTRIAL Not applicable.

  • Open Access

    Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy

    by Jose-Ramon Blanco, Miguel Torralba, María Saumoy, Antonia Alcaraz, Mariano Matarranz del Amo, Julian Olalla, Fernando Dronda, Nisa Boukichou-Abdelkader, Enrique Bernal, Sergio Padilla, et al.

    Background: Currently, integrase strand-transfer inhibitors (INSTIs) are the cornerstone of antiretroviral therapy (ART), providing potent viral suppression and good tolerability. Emerging evidence suggests that INSTI-based regimens may exert different effects on immune and metabolic pathways, potentially influencing inflammation and comorbidity risk. This study aimed to evaluate the impact of various first-line INSTI-based regimens on a panel of circulating biomarkers in treatment-naïve individuals with HIV. Methods: We included ART-naïve adults (≥18 years) with confirmed HIV-1 infection initiating a non-boosted INSTI according to the treating physicians’ decisions. The regimen included were bictegravir/emtricitabine/tenofovir alafenamide (BIC/TAF/FTC or Group 1 [G1]), dolutegravir/lamivudine (DTG/3TC or Group 2 [G2]), and dolutegravir/abacavir/lamivudine (DTG/ABC/3TC or Group 3 [G3]). Participants receiving DTG/ABC/3TC were enrolled via the Spanish CoRIS cohort, with samples from the HIV BioBank. Blood samples were collected at baseline and after 48 weeks. Biomarkers were grouped into six categories: pro- and anti-inflammatory cytokines, immune activation, endothelial dysfunction, metabolic markers, and tryptophan catabolism. Changes from baseline were analyzed using Kruskal–Wallis and Dunn’s tests; linear mixed-effects models assessed longitudinal trends. Results: We included 62 participants. All regimens achieved viral suppression and increased CD4 + counts, with the greatest CD4 + gain in G3. At baseline, G3 had higher TNF, CD40, ICAM-1, and lower IL-10 and leptin levels. After 48 weeks, G3 showed a significant increase in IL-10 and greater declines in CD163 and ICAM-1. Mixed models confirmed distinct longitudinal patterns in CD4 + counts, CD163, and IL-10 in G3. Conclusions: All INSTI-based regimens led to immune restoration, but modest differences in biomarker trajectories suggest distinct immunomodulatory effects. The clinical relevance of these differences remains unclear and warrants further study to assess their role in long-term comorbidity risk.

  • Open Access

    Circulating miRNA Signatures Associated with Atherosclerosis and Cardiometabolic Comorbidities in People with HIV

    by Marina Martinez-Velasco, José Francisco Sánchez-Herrero, Laura Ibañez, Pablo Velli, Francisco Manuel Muñoz-Lopez, Mireia Cairó, Angeles Jaen, Roser Font, Xavier Martinez-Lacasa, Josep Royo, et al.

    Background: People with HIV (PWH) experience increased cardiovascular disease driven by chronic inflammation despite suppressive antiretroviral therapy. Circulating microRNAs (miRNAs) have emerged as potential biomarkers of cardiometabolic dysfunction, yet their relevance to HIV-associated atherosclerosis remains unclear. Methods: We analyzed PWH PBMC-derived miRNAs in two independent cohorts: the HUMT cohort (N = 185), characterized by carotid ultrasound assessment of atheroma plaque and carotid intima–media thickness (cIMT), and the CoRIS cohort (N = 119), stratified by cardiometabolic comorbidity burden (≥3 comorbidities vs none). An exploratory miRNA microarray comparing individuals with and without atheroma plaque (AP+ vs. AP−, N = 72) identified candidate miRNAs, a subset of which was selected for validation by RT-qPCR. Associations with atherosclerosis, cardiometabolic comorbidities and the HIV-adapted COMVIH-CoR clinical cardiovascular risk score were examined. Results: Forty-four miRNAs were differentially expressed in AP+ vs. AP– in the microarray. RT-qPCR validation showed sex-specific miRNA association with miR-638 was consistently downregulated in AP+ and pathological cIMT among men, while reduced expression of miR-27b-5p and miR-3613-5p was observed in women. Associations between miRNAs and cardiometabolic comorbidities differed by cohort: in HUMT, miR-638 was reduced in diabetes and obesity, while miR-140-5p and miR-27b-5p were decreased in smokers and individuals with low HDL. CoRIS participants with multiple comorbidities showed a generalized miRNAs upregulation. Notably, miR-140-5p was consistently elevated in individuals with high COMVIH-CoR scores across both cohorts. Conclusions: PBMC-derived miRNAs capture heterogeneous, context-dependent dimensions of cardiovascular risk in PWH, likely reflecting cumulative immune-metabolic stress rather than universal diagnostic markers of subclinical atherosclerosis and supporting a phenotype-specific role.

  • Open Access

    Prevalence of frailty in people living with HIV over 60 years old in southern Spain

    by Julián Olalla, Yamal Jamal-Ismail, Santiago Vico, Pedro Alarcón, Javier Arenas-Villafranca, Alfonso Del Arco, Javier Pérez-Stachowski, Francisco Rivas-Ruiz, María Dolores Martín-Escalante

    This cross-sectional study aims to describe the prevalence of frailty and pre-frailty in a cohort of people living with HIV in southern Spain. Patients were classified according to Fried frailty phenotype. Questionnaires on anxiety and depression (Hospital Anxiety and Depression scale), loneliness (University of California), resilience (Connor–Davidson Resilience Scale [10-item version]), and socioeconomic information were collected from the participants, their medical history was reviewed to collect comorbidities, non-AIDS events, and drug use. A cluster analysis was conducted to identify participants most likely to be frail. Fifty-two patients were recruited, mostly men, median age 64 years. Four patients were identified as frail (7.7%), 26 as pre-frail (50%), and 22 as robust (43.3%). Frailty was associated with lower socioeconomic level, loneliness, anxiety, depression, and insomnia. Diabetes mellitus was present in all frail patients, and the number of non-antiretroviral medications was higher too. Cluster analysis revealed that the presence of high triglyceride levels and low glomerular filtration rate or high body mass index predicted the presence of frailty. Frailty is associated with certain social and neuropsychiatric characteristics that must be considered. We provide a simple tool to identify those individuals for whom the frailty screening should be started.


  • Open Access

    Lung ultrasound alterations six months after COVID-19 pneumonia: a descriptive study

    by Francisco Navarro-Romero, Cristina Asencio-Méndez, María Dolores Martín-Escalante, Francisco Martos-Pérez, Julián Olalla-Sierra

    The primary aim of this study was to describe the prevalence and characteristics of lung ultrasound abnormalities six months after hospital discharge for COVID-19 pneumonia. This prospective observational study included patients hospitalised with COVID-19 pneumonia between March 2020 and May 2022. Participants attended a follow-up visit between one and six months after discharge. A standardised 14-zone ultrasound protocol was applied in all cases. Clinical variables and symptoms, including dyspnoea graded using the modified Medical Research Council (mMRC) scale, were recorded. The median time from discharge to follow-up assessment was 75 days. Lung involvement on ultrasound was frequent, observed in 79.3%. The most common findings were pleural line irregularities with B-lines (75.9%) and subpleural consolidations (35.6%). A B-line count ≥ 3 per segment was noted in 38.3%. Abnormalities were more common in the basal lung regions. Dyspnoea was the main respiratory symptom, reported by 67% with varying degrees on the mMRC scale. COVID-19 pneumonia remains a significant public health concern, particularly among high-risk groups susceptible to severe disease and post-COVID sequelae. Efficient screening methods are needed for evaluating potential sequelae. The technical features of lung ultrasound—its accessibility, safety, reproducibility, and ability to detect pulmonary abnormalities during post-COVID follow-up—may render it a valuable tool for patient monitoring. In our series, lung ultrasound findings (pleural line irregularities, B-lines, and subpleural consolidations) were frequent. However, further studies correlating sonographic findings with associated factors and persistent symptoms are required to confirm and validate its role in this setting.


  • Open Access

    Profile of suicides in a spanish cohort of people living with HIV (PLWH)

    by Julián Olalla, Joaquim Peraire, Roberto Carlos Güerri Fernández, Naya Faro, Antonia Maria Castillo-Navarro, Pepa Galindo, Nuria Espinosa, Javier Pérez-Stachowski, Alfonso del Arco, Javier de la Torre, et al.